Wu Mingquan, Lai Huabing, Peng Wei, Zhou Xu, Zhu Liyang, Tu He, Yuan Kezhu, Yang Zhirui
Department of Pharmacy, Sichuan Orthopedic Hospital, Chengdu, Sichuan, China.
Department of Rehabilitation and Prosthetic Orthopedics Center, Sichuan Orthopedic Hospital, Chengdu, Sichuan, China.
Front Pharmacol. 2023 Mar 2;14:1109940. doi: 10.3389/fphar.2023.1109940. eCollection 2023.
Monotropein, a principal natural compound in iridoid glycosides extracted from radix, has potent pharmacological activities. To understand and utilize monotropein, we systematically summarized the studies on monotropein, including its biosynthetic pathway, physicochemical properties, pharmacokinetics, and pharmacology. Interestingly, we found that the multiple bioactivities of monotropein, such as anti-osteoporosis, anti-inflammation, anti-oxidation, anti-nociception, and hepatic or renal protection, are closely associated with its capability of downregulating the nuclear factor-κB signaling pathway, inhibiting the mitogen-activated protein kinase signaling pathway, attenuating the activation of nuclear factor E2-related factor 2/heme oxygenase-1 signaling pathway, and regulating the mammalian target of rapamycin/autophagy signaling pathway. However, the clinically therapeutic effects and the potential problems need to be addressed. This review highlights the current research progress on monotropein, which provides a reference for further investigation of monotropein.
梓醇是从地黄中提取的环烯醚萜苷类的主要天然化合物,具有强大的药理活性。为了了解和利用梓醇,我们系统地总结了关于梓醇的研究,包括其生物合成途径、理化性质、药代动力学和药理学。有趣的是,我们发现梓醇的多种生物活性,如抗骨质疏松、抗炎、抗氧化、抗伤害感受以及肝脏或肾脏保护作用,与其下调核因子κB信号通路、抑制丝裂原活化蛋白激酶信号通路、减弱核因子E2相关因子2/血红素加氧酶-1信号通路的激活以及调节雷帕霉素哺乳动物靶标/自噬信号通路的能力密切相关。然而,其临床治疗效果和潜在问题仍有待解决。本综述重点介绍了梓醇的当前研究进展,为进一步研究梓醇提供了参考。